{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:44Z","timestamp":1788415964896,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic therapies targeting the interleukin-5 (IL-5) pathway improve asthma control and chronic rhinosinusitis with nasal polyposis (CRSwNP) in patients with non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD). However, their effect on NSAID tolerance remains insufficiently characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate whether anti-IL-5\/IL-5 receptor (IL-5R) treatments could improve NSAID tolerance in patients with NERD and Blended Reactions (BRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Clinical parameters, including the Asthma Control Test (ACT), 22-item Sino-Nasal Outcome Test (SNOT-22), visual analog scale (VAS) scores for quality of life, nasal polyp grade, and inhaled corticosteroid\/long-acting \u03b22-agonist (ICS\/LABA) dose, were compared before and after biologic therapy. ASA provocation tests were repeated during biologic treatment and compared with prior challenge results; outcomes were also compared between the biologic-treated group and the biologic-naive comparison group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients who received biological treatments showed significant improvements compared to baseline, with eosinophil counts decreasing from 695 (590\u2013892.5) to 50 (30\u201360), ACT scores increasing from 12 (8.7\u201318) to 24 (20.7\u201324.2), SNOT-22 scores declining from 56 (51\u201373) to 16 (5.7\u201328.7), and VAS scores improving from 1 (0\u20132.2) to 9 (7\u201310), all with p=0.001. ASA provocation positivity decreased to 28.5% (p=0.002), and all patients stepped down from high-dose to medium\/low-dose ICS\/LABA. Among the four patients who remained intolerant, reactions occurred at higher cumulative doses, with delayed onset and milder symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study indicated that blockade of IL-5 pathway significantly improved clinical outcomes and reduced ASA hypersensitivity in patients with NERD\/BRs, highlighting their potential role in modifying disease phenotype beyond asthma control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1950229","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:15:37Z","timestamp":1788412537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-5\/IL-5R blockade enables safe non-steroidal anti-inflammatory agent reintroduction in non-steroidal anti-inflammatory exacerbated respiratory disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Pelin","family":"Korkmaz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevzat","family":"Kahveci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Ozan","family":"Yegit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Hormet","family":"Igde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet E.","family":"Sezgin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse F.","family":"Aslan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bircan","family":"Erden","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Bolek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve D.","family":"Atasever","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin E.","family":"Guzel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eule \u00c7elik","family":"Kamac\u0131","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131","family":"Gelincik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7437.434","article-title":"Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice","volume":"328","author":"Jenkins","year":"2004","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/all.12941","article-title":"Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA(2) LEN) survey","volume":"71","author":"Makowska","year":"2016","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16710","DOI":"10.1038\/s41598-018-34668-1","article-title":"NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs","volume":"8","author":"Dona","year":"2018","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.12689","article-title":"Evaluation of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs according to the latest classification","volume":"70","author":"Demir","year":"2015","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101086","article-title":"Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO statement","volume":"18","author":"Romano","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2012.26.3792","article-title":"Aeroallergen sensitization influences quality of life and comorbidities in patients with nasal polyposis","volume":"26","author":"Davila","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61782-6","article-title":"Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma","volume":"92","author":"Kupczyk","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2022.14.2.153","article-title":"Emerging biomarkers beyond leukotrienes for the management of nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease","volume":"14","author":"Rhyou","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2019.11.6.779","article-title":"Complementary participation of genetics and epigenetics in development of NSAID-exacerbated respiratory disease","volume":"11","author":"Lee","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201310-354OC","article-title":"Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma","volume":"11","author":"Katz","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00192.x","article-title":"The eosinophil and airway remodelling in asthma","volume":"4","author":"Venge","year":"2010","journal-title":"Clin Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4861","article-title":"Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells","volume":"177","author":"Pegorier","year":"2006","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568541","article-title":"Inflammatory and homeostatic roles of eosinophil subpopulations in chronic rhinosinusitis with nasal polyp pathogenesis","volume":"16","author":"Simmalee","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.otoeng.2024.08.001","article-title":"Real-world outcomes on quality-of-life improvement in patients with nasal polyposis treated with mepolizumab. RINOSUR study","volume":"76","author":"Maza-Solano","year":"2025","journal-title":"Acta Otorrinolaringol Esp (Engl Ed)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B18","article-title":"Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease","volume":"25","author":"Guillen","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.013","article-title":"Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab","volume":"5","author":"Phillips-Angles","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: A randomized comparative trial","volume":"11","author":"Sanchez","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01335-2022","article-title":"Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease","volume":"61","author":"Schneider","year":"2023","journal-title":"Eur Respir J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-024-3260-7","article-title":"Global initiative for asthma guidelines 2024: An update","volume":"61","author":"Rajvanshi","year":"2024","journal-title":"Indian Pediatr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01409.x","article-title":"EAACI\/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity","volume":"62","author":"Nizankowska-Mogilnicka","year":"2007","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01147","article-title":"NSAID-exacerbated respiratory disease (NERD): From pathogenesis to improved care","volume":"11","author":"Woo","year":"2020","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02261.x","article-title":"Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity","volume":"35","author":"Cormican","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2012.10.008","article-title":"Classification of reactions to nonsteroidal antiinflammatory drugs","volume":"33","author":"Kowalski","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"B27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4045\/tidsskr.13.1145","article-title":"VAS--visual analog scale","volume":"134","author":"Faiz","year":"2014","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","article-title":"Key recommendations for primary care from the 2022 global initiative for asthma (GINA) update","volume":"33","author":"Levy","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.03.014","article-title":"Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma","volume":"107","author":"Karakaya","year":"2013","journal-title":"Respir Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","article-title":"Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment","volume":"404","author":"Zuberbier","year":"2024","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/all.16499","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence","volume":"80","author":"Cai","year":"2025","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16087","article-title":"Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial","volume":"90","author":"Emson","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1950229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:15:39Z","timestamp":1788412539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1950229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1950229"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1950229","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1950229"}}